Drugs of abuse and ocular effects

References

• Canadian Tobacco. Alcohol and drugs (CTADS) Survey 2017. Statistics Canada; 2019. Available from: https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary/2017-detailed-tables.html#t13
   Google Scholar
• Canadian Tobacco. Alcohol and drugs (CTADS) survey 2015. Statistics Canada; 2017. Available from: https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2015-supplementary-tables.html#a14
   Google Scholar
• Patel SN, Rescigno RJ, Zarbin MA, et al. Endogenous endophthalmitis associated with intravenous drug abuse. Retina. 2014;34:1460–1465.
   PubMed Web of Science ®Google Scholar
• Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis. 1998;27:1130–1133.
   PubMed Web of Science ®Google Scholar
• Shankland GS, Richardson MD. Epidemiology of an outbreak of Candida endophthalmitis in heroin addicts: identification of possible source of infection by biotyping. J Med Vet Mycol. 1988;26:199–202.
   PubMedGoogle Scholar
• Dupont B, Drouhet E. Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients. J Infect Dis. 1985;152:577–591.
   PubMed Web of Science ®Google Scholar
• Tirpack AR, Duker JS, Baumal CR. An outbreak of endogenous fungal endophthalmitis among intravenous drug abusers in New England. JAMA Ophthalmol. 2017;135:534–540.
   Web of Science ®Google Scholar
• Relhan N, Schwartz SG, Flynn HW. Endogenous fungal endophthalmitis: an increasing problem among intravenous drug users. JAMA. 2017;318:741–742.
   PubMed Web of Science ®Google Scholar
• Connell PP, O’Neill EC, Fabinyi D, et al. Endogenous endophthalmitis: 10-year experience at a tertiary referral centre. Eye. 2011;25:66–72.
   PubMed Web of Science ®Google Scholar
• Narendran N, Balasubramaniam B, Johnson E, et al. Five-year retrospective review of guideline-based management of fungal endophthalmitis. Acta Ophthalmol. 2008;86:525–532.
   PubMed Web of Science ®Google Scholar
• Doft BH, Clarkson JG, Rebell G, et al. Endogenous Aspergillus endophthalmitis in drug abusers. Arch Ophthalmol. 1980;98:859–862.
   PubMed Web of Science ®Google Scholar
• Albini TA, Sun RL, Holz ER, et al. Lemon juice and Candida endophthalmitis in crack-cocaine misuse. Br J Ophthalmol. 2007;91:702–703.
   Web of Science ®Google Scholar
• Connell PP, O’neill EC, Amirul Islam FM, et al. Endogenous endophthalmitis associated with intravenous drug abuse: seven-year experience at a tertiary referral center. Retina. 2010;30:1721–1725.
   PubMed Web of Science ®Google Scholar
• Rondon-Berrios H, Khilnani N, Trevejo-Nunez GJ. Disseminated candidiasis in intravenous drug abusers: A distinctive syndrome. Adv Stud Med. 2006;6:191–194.
   Google Scholar
• Doan T, Vemulakonda GA, Choi D, et al. Retinal neovascularization and endogenous fungal endophthalmitis in intravenous drug users. Ophthalmology. 2014;121:1847–1848.e1842.
   Web of Science ®Google Scholar
• Tran KH, Ilsen PF. Peripheral retinal neovascularization in talc retinopathy. Optometry. 2007;78:409–414.
   Google Scholar
• Fraser-Bell S, Capon M. Talc retinopathy. Clin Exp Ophthalmol. 2002;30:432–433.
   Web of Science ®Google Scholar
• Sharma MC, Ho AC. Macular fibrosis associated with talc retinopathy. Am J Ophthalmol. 1999;128:517–519.
   Web of Science ®Google Scholar
• O’Brien RJ, Schroedl BL. Talc retinopathy. Optom Vis Sci. 1991;68:54–57.
   Web of Science ®Google Scholar
• Tse DT, Ober RR. Talc retinopathy. Am J Ophthalmol. 1980;90:624–640.
   PubMed Web of Science ®Google Scholar
• Zoumalan CI, Marmor MF. Revisiting talc retinopathy. Arch Ophthalmol. 2007;125:988.
   Google Scholar
• Shah VA, Cassell M, Poulose A, et al. Talc retinopathy. Ophthalmology. 2008;115:755–755.e752.
   Web of Science ®Google Scholar
• Kumar RL, Kaiser PK, Lee MS. Crystalline retinopathy from nasal ingestion of methamphetamine. Retina. 2006;26:823–824.
   PubMed Web of Science ®Google Scholar
• Parver LM, Dannenberg AL, Blacklow B, et al. Characteristics and causes of penetrating eye injuries reported to the National Eye Trauma System Registry, 1985-91. 433021. 1993;108:625–632.
   Google Scholar
• Chang SL, Patel V, Giltner J, et al. The relationship between ocular trauma and substance abuse in emergency department patients. Am J Emerg Med. 2017;35:1734–1737.
   Web of Science ®Google Scholar
• Lim M, Kent D, Clark D. An unusual case of ocular self-injury [4]. Eye. 2001;15:660–661.
   Web of Science ®Google Scholar
• Shah M, Sun L, Elmann S, et al. Self-inflicted enucleations: clinical features of seven cases. Orbit. 2017;36:154–158.
   PubMed Web of Science ®Google Scholar
• What is cocaine? National institute of drugs abuse - advancing addiction science. 2016. [cited 2020 Jul 7]. Available from: https://www.drugabuse.gov/publications/research-reports/cocaine/what-cocaine
   Google Scholar
• Cocaine (Canadian Drug Summary). Canadian center on substance abuse and addiction. 2019. [cited 2020 Jul 7]. Available from: https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Canadian-Drug-Summary-Cocaine-2019-en.pdf
   Google Scholar
• Kalin-Hajdu E, Allaire G, Boulos PR. Ocular penetration secondary to cocaine-induced midline destructive lesion. Ophthalmic Plast Reconstr Surg. 2017;33:e23–e26.
   Web of Science ®Google Scholar
• Gatt K, Vella SM, Fenech M, et al. Infective complications of midline destruction in a cocaine user. BMJ Case Rep. 2019 Jul 26;12(7):e231743.
   Google Scholar
• Siemerink MJ, Freling NJM, Saeed P. Chronic orbital inflammatory disease and optic neuropathy associated with long-term intranasal cocaine abuse: 2 cases and literature review. Orbit. 2017;36:350–355.
   PubMed Web of Science ®Google Scholar
• Shen CC, Silver AL, O’Donnell TJ, et al. Optic neuropathy caused by naso-orbital mass in chronic intranasal cocaine abuse. J Neuroophthalmol. 2009;29:50–53.
   PubMed Web of Science ®Google Scholar
• Neugebauer P, Fricke J, Neugebauer A, et al. Sinuorbital complications after intranasal cocaine abuse. Strabismus. 2004;12:205–209.
   PubMedGoogle Scholar
• Underdahl JP, Chiou AG. Preseptal cellulitis and orbital wall destruction secondary to nasal cocaine abuse. Am J Ophthalmol. 1998;125:266–268.
   PubMed Web of Science ®Google Scholar
• Alexandrakis G, Tse DT, Rosa RH Jr., et al. Nasolacrimal duct obstruction and orbital cellulitis associated with chronic intranasal cocaine abuse. Arch Ophthalmol. 1999;117:1617–1622.
   PubMedGoogle Scholar
• Goldberg RA, Weisman JS, McFarland JE, et al. Orbital inflammation and optic neuropathies associated with chronic sinusitis of intranasal cocaine abuse. Possible role of contiguous inflammation. Arch Ophthalmol. 1989;107:831–835.
   PubMedGoogle Scholar
• Latasiewicz M, Chang-Sotomayor M, Alonso-Caldarelli C, et al. Bilateral self-inflicted infectious dacryoadenitis. Orbit. 2014;33:465–467.
   PubMedGoogle Scholar
• Miller AD, Sherman SC. Crack eye. J Emerg Med. 2009;37:75–76.
   PubMed Web of Science ®Google Scholar
• Ehrenhaus M, Demoz A. Woman with Painful, Red Eyes. Consultant. 2004;44:26+29.
   Google Scholar
• Stuard WL, Gallerson BK, Robertson DM. Alterations in corneal nerves following crack cocaine use mimic diabetes-induced nerve damage. Endocrinol Diabetes Metab Case Rep. 2017 Mar 16;2017:16–131.
   Google Scholar
• Zhou M, Farooq AV, Andreoli MT, et al. Bilateral Rhizopus keratitis in a cocaine user. Can J Ophthalmol. 2016;51:e21–23.
   PubMed Web of Science ®Google Scholar
• Mantelli F, Lambiase A, Sacchetti M, et al. Cocaine snorting may induce ocular surface damage through corneal sensitivity impairment. Graefes Arch Clin Exp Ophthalmol. 2015;253:765–772.
   Web of Science ®Google Scholar
• da Silva CM, de Sousa RA, Baptista AM. Assessment of tear amount in subjects under the effect of (inhaled) cocaine. J Psychoactive Drugs. 2013;45:195–198.
   PubMed Web of Science ®Google Scholar
• Ghosheh FR, Ehlers JP, Ayres BD, et al. Corneal ulcers associated with aerosolized crack cocaine use. Cornea. 2007;26:966–969.
   PubMed Web of Science ®Google Scholar
• Sachs R, Zagelbaum BM, Hersh PS. Corneal complications associated with the use of crack cocaine. Ophthalmology. 1993;100:187–191.
   PubMed Web of Science ®Google Scholar
• Strominger MB, Sachs R, Hersh PS. Microbial keratitis with crack cocaine. Arch Ophthalmol. 1990;108:1672.
   PubMedGoogle Scholar
• Vasconcelos SB, Guerra FM, Morato GM, et al. Acquired anterior staphyloma after corneal ulcer associated with the use of crack. Arq Bras Oftalmol. 2016;79:268–269.
   PubMed Web of Science ®Google Scholar
• Valmaggia C, Gottlob IM. Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil. Strabismus. 2001;9:9–12.
   PubMedGoogle Scholar
• Obeidat AZ. Cocaine as a potential trigger for Neuromyelitis Optica. J Neurol Sci. 2018;390:99–101.
   Web of Science ®Google Scholar
• Migita DS, Devereaux MW, Tomsak RL. Cocaine and pupillary-sparing oculomotor nerve paresis. Neurology. 1997;49:1466–1467.
   Web of Science ®Google Scholar
• Elkardoudi-Pijnenburg Y, Van Vliet A. Opsoclonus, a rare complication of cocaine misuse [8]. J Neurol Neurosurg Psychiatry. 1996;60:592.
   Web of Science ®Google Scholar
• Diaz-Calderon E, Del Brutto OH, Aguirre R, et al. Bilateral internuclear ophthalmoplegia after smoking “crack” cocaine. J Clin Neuroophthalmol. 1991;11:297–299.
   Google Scholar
• Iyer S, Tay ET, Maslyanskaya S. Anisocoria from cocaine exposure: a case report. J Emerg Med. 2019;56:e17–e18.
   Web of Science ®Google Scholar
• Siegel RK. Cocaine smoking. J Psychoactive Drugs. 1992;24:183–192.
   Web of Science ®Google Scholar
• Mitchell JD, Schwartz AL. Acute angle-closure glaucoma associated with intranasal cocaine abuse. Am J Ophthalmol. 1996;122:425–426.
   Web of Science ®Google Scholar
• Kumar BV, Dhir S, Prasad SD. Spontaneous hyphaema: blunt trauma and cocaine abuse. Eye. 2006;20:1377.
   Web of Science ®Google Scholar
• Karasavvidou EA, Athanasopoulos GP, Konstas AG, et al. Valsalva retinopathy associated with intranasal cocaine abuse: A case report. Eur J Ophthalmol. 2019;29: NP5-NP8.
   Web of Science ®Google Scholar
• Kannan B, Balaji V, Kummararaj S, et al. Cilioretinal artery occlusion following intranasal cocaine insufflations. Indian J Ophthalmol. 2011;59:388–389.
   Web of Science ®Google Scholar
• Michaelides M, Larkin G. Cocaine-associated central retinal artery occlusion in a young man. Eye. 2002;16:790–792.
   Web of Science ®Google Scholar
• Pinilla I, Abecia E, Borque E, et al. Cocaine-induced preretinal haemorrhage in a young adult. Acta Ophthalmologica Scandinavica. 2007;85:343–344.
   Google Scholar
• Sleiman I, Mangili R, Semeraro F, et al. Cocaine-associated retinal vascular occlusion: report of two cases. Am J Med. 1994;97:198–199.
   PubMed Web of Science ®Google Scholar
• Zeiter JH, Corder DM, Madion MP, et al. Sudden retinal manifestations of intranasal cocaine and methamphetamine abuse. Am J Ophthalmol. 1992;114:780–781.
   Google Scholar
• Introini U, Casalino G, Querques G, et al. Acute macular neuroretinopathy following intranasal use of cocaine. Acta Ophthalmol (Oxf). 2015;93:e239–240.
   Web of Science ®Google Scholar
• Hu Q, Wu X. Eye pain in optic perineuritis. Neuro-Ophthalmology. 2015;39:100.
   Web of Science ®Google Scholar
• Ascaso FJ, Cruz N, Del Buey MA, et al. An unusual case of cocaine-induced maculopathy. Eur J Ophthalmol. 2009;19:880–882.
   Web of Science ®Google Scholar
• Hulka LM, Wagner M, Preller KH, et al. Blue-yellow colour vision impairment and cognitive deficits in occasional and dependent stimulant users. Int J Neuropsychopharmacol. 2013;16:535–547.
   Web of Science ®Google Scholar
• Gemelli H, Fidalgo TM, Gracitelli CPB, et al. Retinal nerve fiber layer analysis in cocaine users. Psychiatry Res. 2019;271:226–229.
   PubMed Web of Science ®Google Scholar
• Rofsky JE, Townsend JC, Ilsen PF, et al. Retinal nerve fiber layer defects and microtalc retinopathy secondary to free-basing “crack” cocaine. J Am Optom Assoc. 1995;66:712–720.
   Google Scholar
• Dhuna A, Pascual-Leone A, Belgrade M. Cocaine-related vascular headaches. J Neurol Neurosurg Psychiatry. 1991;54:803–806.
   PubMed Web of Science ®Google Scholar
• Libman RB, Masters SR, De Paola A, et al. Transient monocular blindness associated with cocaine abuse. Neurology. 1993;43:228–229.
   Web of Science ®Google Scholar
• Rahman W, Thomas S, Wiselka M, et al. Cocaine-induced chorioretinal infarction. Br J Ophthalmol. 2008;92:150–151.
   Web of Science ®Google Scholar
• Drugsfacts abuse Niod. 2019. Available from: https://www.drugabuse.gov/publications/drugfacts/heroin
   Google Scholar
• The Neurobiology of Drug Addiction. abuse Niod. 2019. Available from: https://www.drugabuse.gov/publications/teaching-packets/neurobiology-drug-addiction/section-iii-action-heroin-morphine
   Google Scholar
• Alipour F, Hashemi H, Piri N, et al. Ocular manifestations of transconjunctival heroin abuse: a case report of an unusual route of substance abuse. Cornea. 2010;29:110–112.
   Web of Science ®Google Scholar
• Pujar T, Spinello IM. A 38-year-old woman with heroin addiction, ptosis, respiratory failure, and proximal myopathy. Chest. 2008;134:867–870.
   Web of Science ®Google Scholar
• Vera J, Hensiek A, Woodrow C, et al. Ophthalmoplegia and slurred speech in an intravenous drug user. PLoS Med. 2006;3:e453.
   Web of Science ®Google Scholar
• Jensenius M, Lovstad RZ, Dhaenens G, et al. A heroin user with a wobbly head. Lancet. 2000;356:1160.
   Web of Science ®Google Scholar
• Aktas A, Rojas E, Parikh HA, et al. Myasthenia gravis crisis coinciding with asthma exacerbation in a patient with recent heroin use: three causes of acute hypercarbic respiratory failure. BMJ Case Rep. 2018;07:07.
   Google Scholar
• Ross JJ, Brown V, Fern AI. Variable angle of strabismus related to timing of opiate ingestion. J Aapos. 2009;13:200–201.
   PubMed Web of Science ®Google Scholar
• Iqbal N. Ptosis, convergence disorder and heroin. Ann Saudi Med. 2002;22:369–371.
   Web of Science ®Google Scholar
• Milet A, Blaise P, Andris C, et al. [Bilateral optic atrophy in a drug addict]. J Fr Ophthalmol. 2007;30:e29.
   Web of Science ®Google Scholar
• Bettendorf BA, Thomson M, Reichstein D, et al. Acute central vision loss in an IV drug user. Wmj. 2015;114:69–72.
   Google Scholar
• Ecstasy. Government of Canada; 2018. [cited 2020 Jul 7]. Available from: https://www.canada.ca/fr/sante-canada/services/dependance-aux-drogues/drogues-illicites-et-reglementees/ecstasy.html
   Google Scholar
• Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001;165:917–928.
   PubMed Web of Science ®Google Scholar
• Baalachandran R, Hypes C, Natt B, et al. Pipe dreams: concealed methamphetamine causing severe toxicity. Am J Med Sci. 2015;349:548–549.
   Web of Science ®Google Scholar
• Ecstasy or Molly (MDMA) (Canadian Drug Summary). Health Canada; 2017. [cited 2020 Jul 7]. Available from https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Canadian-Drug-Summary-MDMA-2017-en.pdf
   Google Scholar
• Halpern P, Moskovich J, Avrahami B, et al. Morbidity associated with MDMA (ecstasy) abuse: A survey of emergency department admissions. Hum Exp Toxicol. 2011;30:259–266.
   PubMed Web of Science ®Google Scholar
• Tabatabaei SA, Soleimani M, Khodabandeh A. A case of autoenucleation associated with a contralateral field defect. Orbit. 2011;30:165–168.
   PubMedGoogle Scholar
• Zwick OM, Fischer DH, Flanagan JC. “Ecstasy” induced immunosuppression and herpes zoster ophthalmicus [6]. Br J Ophthalmol. 2005;89:923–924.
   Web of Science ®Google Scholar
• Poulsen EJ, Mannis MJ, Chang SD. Keratitis in methamphetamine abusers. Cornea. 1996;15:477–482.
   PubMed Web of Science ®Google Scholar
• Chuck RS, Williams JM, Goldberg MA, et al. Recurrent corneal ulcerations associated with smokeable methamphetamine abuse. Am J Ophthalmol. 1996;121:571–572.
   PubMed Web of Science ®Google Scholar
• O’Neill D, Datt JK. Methylenedioxyamphetamine (‘Ecstasy’) associated keratopathy [1]. Eye. 1993;7:805–806.
   Web of Science ®Google Scholar
• McCutcheon DS, Oosthuizen FJ, Hoggett KA, et al. A bolt out of the blue: the night of the blue pills. Med J Aust. 2015;202:543.
   Web of Science ®Google Scholar
• Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine-induced psychosis. J Ment Health. 2013;22:341–349.
   PubMed Web of Science ®Google Scholar
• Oliveri M, Calvo G. Increased visual cortical excitability in ecstasy users: A transcranial magnetic stimulation study. J Neurol Neurosurg Psychiatry. 2003;74:1136–1138.
   Web of Science ®Google Scholar
• Logan BK, Couper FJ. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci. 2001;46:1426–1433.
   PubMed Web of Science ®Google Scholar
• Kumar RS, Grigg J, Farinelli AC. Ecstasy induced acute bilateral angle closure and transient myopia. Br J Ophthalmol. 2007;91:693–695.
   PubMed Web of Science ®Google Scholar
• Trittibach P, Frueh BE, Goldblum D. Bilateral angle-closure glaucoma after combined consumption of “ecstasy” and marijuana. Am J Emerg Med. 2005;23:813–814.
   Web of Science ®Google Scholar
• Anderson CA, Sung GY. Central retinal artery occlusion associated with intranasal methamphetamine use. J Stroke Cerebrovasc Dis. 2003;12:207–208.
   Google Scholar
• Guo J, Tang W, Liu W, et al. Bilateral methamphetamine-induced ischemic retinopathy. Retina. 2001;21(5):559–561.
   Google Scholar
• Hassan L, Carvalho C, Yannuzzi LA, et al. Central serous chorioretinopathy in a patient using methylenedioxymethamphetamine (MDMA) or “ecstasy”. Retina. 2001;21:559–561.
   PubMed Web of Science ®Google Scholar
• Schroeder B, Brieden S. Bilateral sixth nerve palsy associated with MDMA (“ecstasy”) abuse. Am J Ophthalmol. 2000;129:408–409.
   Web of Science ®Google Scholar
• Shaw HE Jr., Lawson JG, Stulting RD. Amaurosis fugax and retinal vasculitis associated with methamphetamine inhalation. J Clin Neuroophthalmol. 1985;5:169–176.
   PubMedGoogle Scholar
• Wijaya J, Salu P, Leblanc A, et al. Acute unilateral visual loss due to a single intranasal methamphetamine abuse. Bull Soc Belge Ophtalmol. 1999;271:19–25.
   PubMedGoogle Scholar
• Dominici P, Kopec K, Manur R, et al. Phencyclidine intoxication case series study. J Med Toxicol. 2015;11:321–325.
   PubMed Web of Science ®Google Scholar
• Stratton MA, Witherspoon JM, Kirtley T. Hypertensive crisis and phencyclidine abuse. Va Med. 1978;105:569–572.
   Google Scholar
• Ketamine. Centre for addiction and mental health. [cited 2020 Jul 7]. Available from: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/ketamine
   Google Scholar
• Hofer KE, Grager B, Muller DM, et al. Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med. 2012;60:97–99.
   PubMed Web of Science ®Google Scholar
• Thornton S, Lisbon D, Lin T, et al. Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs. 2017;49:289–293.
   PubMed Web of Science ®Google Scholar
• Backberg M, Beck O, Helander A. Phencyclidine analog use in Sweden - Intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol. 2015;53:856–864.
   PubMed Web of Science ®Google Scholar
• Ward J, Rhyee S, Plansky J. Methoxetamine: A novel ketamine analog and growing health-care concern. Clin Toxicol. 2011;49:874–875.
   PubMed Web of Science ®Google Scholar
• Cheng WC, Ng KM, Chan KK, et al. Roadside detection of impairment under the influence of ketamine–evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci Int. 2007;170:51–58.
   PubMed Web of Science ®Google Scholar
• Weiner AL, Vieira L, McKay CA Jr, et al. Ketamine abusers presenting to the Emergency Department: A case series. J Emerg Med. 2000;18:447–451.
   PubMed Web of Science ®Google Scholar
• Radant AD, Bowdle TA, Cowley DS, et al. Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology. 1998;19:434–444.
   PubMed Web of Science ®Google Scholar
• Ubogu E. Amaurosis fugax associated with phencyclidine inhalation. Eur Neurol. 2001;46:98–99.
   Web of Science ®Google Scholar
• Birmes P, Chounet V, Mazerolles M, et al. Self-poisoning with Datura stramonium: 3 case reports. [French]. Presse Med. 2002;31:69–72.
   PubMed Web of Science ®Google Scholar
• Arefi M, Barzegari N, Asgari M, et al. Datura poisoning, clinical and laboratory findings. Report of five cases. Romanian J Legal Med. 2016;24:308–311.
   Web of Science ®Google Scholar
• Wiebe TH, Sigurdson ES, Katz LY. Angel’s Trumpet (Datura stramonium) poisoning and delirium in adolescents in Winnipeg, Manitoba: summer 2006. Paediatr Child Health. 2008;13:193–196.
   PubMed Web of Science ®Google Scholar
• United Nations. World Drug Report. New York: Crime UNOoDa ed; 2013.
   Google Scholar
• Beno S, Osterhoudt KC, Meaney P. An exceedingly agitated patient. Pediatr Emerg Care. 2004;20:845–848.
   Web of Science ®Google Scholar
• Kurzbaum A, Simsolo C, Kvasha L, et al. Toxic delirium due to Datura stramonium. Isr Med Assoc J. 2001;3:538–539.
   Web of Science ®Google Scholar
• Guharoy SR, Barajas M. Atropine intoxication from the ingestion and smoking of jimson weed (Datura stramonium). Vet Hum Toxicol. 1991;33:588–589.
   PubMedGoogle Scholar
• Montcriol A, Kenane N, Delort G, et al. Intentional Datura stramonium intoxication: an unknown etiology of mydriasis. Ann Fr Anesth Reanim. 2007;26:810–813.
   PubMedGoogle Scholar
• Singh S, Kosana D, Lal R. Long-term intentional Datura use and its consequences. Indian J Psychiatry. 2019;61:543–544.
   Web of Science ®Google Scholar
• Weir E. Inhalant use and addiction in Canada. CMAJ. 2001;164:397.
   Web of Science ®Google Scholar
• Health Canada. Canadian alcohol and drug use monitoring survey. 2012. [cited 2020 Jul 7]. Available from: https://www.ccsa.ca/canadian-addiction-survey-cas-national-survey-canadians-use-alcohol-and-other-drugs-prevalence-0
   Google Scholar
• Gundogan FC, Gorgun E, Oz O, et al. Toluene related toxic optic neuropathy. Neuro-Ophthalmology. 2009;33:248–252.
   Web of Science ®Google Scholar
• Coleman H, Charles G, Collins J. Inhalant use by Canadian Aboriginal youth. J Child Adolesc Subst Abuse. 2001;10:1–20.
   Web of Science ®Google Scholar
• Gupta SR, Palmer CA, Cure JK, et al. Toluene optic neurotoxicity: magnetic resonance imaging and pathologic features. Hum Pathol. 2011;42:295–298.
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y. Cerebellar dysfunction in chronic toluene abuse: beneficial response to amantadine hydrochloride. J Toxicol Clin Toxicol. 2000;38:37–41.
   PubMed Web of Science ®Google Scholar
• Kiyokawa M, Mizota A, Takasoh M, et al. Pattern visual evoked cortical potentials in patients with toxic optic neuropathy caused by toluene abuse. Jpn J Ophthalmol. 1999;43:438–442.
   Web of Science ®Google Scholar
• Ogawa Y, Takatsuki R, Uema T, et al. Acute optic neuropathy induced by thinner sniffing: inhalation of mixed organic solvent containing methyl alcohol and methyl acetate. Ind Health. 1988;26:239–244.
   Web of Science ®Google Scholar
• Mohd Isa MF, Mohd Zain NR, Gaillard F, et al. Toluene dependency, psychosis, and cerebellar syndrome. J Neuropsychiatry Clin Neurosci. 2013;25:E42–E43.
   Web of Science ®Google Scholar
• Cairney S, Maruff P, Burns CB, et al. Saccade dysfunction associated with chronic petrol sniffing and lead encephalopathy. J Neurol Neurosurg Psychiatry. 2004;75:472–476.
   PubMed Web of Science ®Google Scholar
• Poblano A, Ishiwara K, Ortega P, et al. Thinner abuse alters optokinetic Nystagmus parameters. Arch Med Res. 2000;31:182–185.
   Web of Science ®Google Scholar
• King MD, Day RE, Oliver JS, et al. Solvent encephalopathy. Br Med J (Clin Res Ed). 1981;283:663–665.
   PubMed Web of Science ®Google Scholar
• Ivis FJ, Adlaf EM. A. Comparison of trends in drug use among students in the USA and Ontario, Canada: 1975-1997. Drugs: Educ Prev Policy. 1999;6:17–27.
   Web of Science ®Google Scholar
• Szlatenyi CS, Wang RY. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation. Am J Emerg Med. 1996;14:464–466.
   Web of Science ®Google Scholar
• Rao NP, Gupta A, Sreejayan K, et al. Toluene associated schizophrenia-like psychosis. Indian J Psychiatry. 2009;51:329–330.
   Google Scholar
• Twardowschy CA, Teive HA, Siquineli F, et al. Optic neuritis due to solvent abuse. Arq Neuropsiquiatr. 2008;66:108–110.
   Web of Science ®Google Scholar
• LSD. Government of Canada. 2018. [cited 2020 Jul 7]. Available from: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/lsd.html
   Google Scholar
• Lo D, Cobbs L, Chua M, et al. “Eye dropping”-a case report of transconjunctival lysergic acid diethylamide drug abuse. Cornea. 2018;37:1324–1325.
   Web of Science ®Google Scholar
• Quin GI, Fanning NF, Plunkett PK. Nutmeg intoxication [5]. J Accid Emerg Med. 1998;15:287–288.
   PubMedGoogle Scholar
• Ehrenpreis JE, DesLauriers C, Lank P, et al. Nutmeg poisonings: a retrospective review of 10 years experience from the Illinois Poison Center, 2001-2011. J Med Toxicol. 2014;10:148–151.
   PubMedGoogle Scholar
• Abernethy MK, Becker LB. Acute nutmeg intoxication. Am J Emerg Med. 1992;10:429–430.
   PubMed Web of Science ®Google Scholar
• Clemens CR, Alten F, Loos D, et al. Poppers maculopathy or retinopathy? Eye. 2015;29:148–149.
   PubMed Web of Science ®Google Scholar
• Schwartz C. Vapour and Mirrors: poppers in the context of Canadian drug policy; 2019. [cited 2020 Jul 7]. Available from: https://www.cbrc.net/vapour_and_mirrors_poppers_in_the_context_of_canadian_drug_policy.
   Google Scholar
• Krilis M, Thompson J, Atik A, et al. ‘Popper’-induced vision loss. Drug Alcohol Rev. 2013;32:333–334.
   Web of Science ®Google Scholar
• Health Canada. Multiple unauthorized “poppers” and sexual enhancement products seized from Scarborough and Etobicoke adult stores may pose serious health risks. 2017. [cited 2020 Jul 7]. Available from: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63738a-eng.php
   Google Scholar
• Asensio-Sanchez VM, Gonzalez-Buendia L, Marcos-Fernandez M. NOT ESPAGNOL Maculopathy due to drug inhalation. Arch Soc Esp Oftalmol. 2014;89:313–315.
   Google Scholar
• Audo I, El Sanharawi M, Vignal-Clermont C, et al. Foveal damage in habitual poppers users. Arch Ophthalmol. 2011;129:703–708.
   PubMed Web of Science ®Google Scholar
• Bral NO, Marinkovic M, Leroy BP, et al. Do not turn a blind eye to alkyl nitrite (poppers)! Acta Ophthalmol (Oxf). 2016;94:e82–83.
   PubMed Web of Science ®Google Scholar
• Bruninx R, Lepiece G. Didactic image poppers maculopathy. Bull Soc Belge Ophtalmol. 2013;322:133–135.
   Google Scholar
• Davies AJ, Kelly SP, Bhatt PR. ‘Poppers maculopathy’–an emerging ophthalmic reaction to recreational substance abuse. Eye. 2012;26:888.
   PubMed Web of Science ®Google Scholar
• Davies AJ, Kelly SP, Naylor SG, et al. Adverse ophthalmic reaction in poppers users: case series of ‘poppers maculopathy’. Eye. 2012;26:1479–1486.
   PubMed Web of Science ®Google Scholar
• Docherty G, Eslami M, O’Donnell H. “Poppers Maculopathy”: a case report and literature review. Can J Ophthalmol. 2018;53:e154–e156.
   PubMed Web of Science ®Google Scholar
• Gruener AM, Jeffries MA, El Housseini Z, et al. Poppers maculopathy. Lancet. 2014;384:1606.
   PubMed Web of Science ®Google Scholar
• Luis J, Virdi M, Nabili S. Poppers retinopathy. BMJ Case Rep. 2016;07:07.
   Google Scholar
• Rabot A, Pinon F, Baillif S. [SD-OCT appearance in acute poppers-associated macular toxicity]. J Fr Ophtalmol. 2013;36:388–389.
   PubMed Web of Science ®Google Scholar
• Van Bol LB, Kurt RA, Keane PA, et al. Clinical phenotypes of poppers maculopathy and their links to visual and anatomic recovery. Ophthalmology. 2017;124:1425–1427.
   PubMed Web of Science ®Google Scholar
• Vignal-Clermont C, Audo I, Sahel JA, et al. Poppers-associated retinal toxicity. N Engl J Med. 2010;363:1583–1585.
   PubMed Web of Science ®Google Scholar
• Dyrda A, Catala-Mora J, Rey A, et al. Macular hole after poppers (alkyl nitrate) inhalation in a child. Ophthalmic Surg Lasers Imaging Retina. 2018;49:897–900.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum MA. Is the mechanism of ‘poppers maculopathy’ photic injury? Eye. 2013;27:1420–1421.
   PubMed Web of Science ®Google Scholar
• Richeval C, Boucher A, Humbert L, et al. Retrospective identification of 25I-NBOMe metabolites in an intoxication case. Toxicologie Analytique et Clinique. 2017;29:71–81.
   Google Scholar
• Helander A, Bradley M, Hasselblad A, et al. Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. Br J Dermatol. 2017;176:1021–1027.
   Web of Science ®Google Scholar
• Helander A, Backberg M, Beck O. MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin Toxicol. 2014;52:901–904.
   PubMed Web of Science ®Google Scholar
• Khaled SM, Hughes E, Bressington D, et al. The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol. Syst Rev. 2016;5:195.
   PubMed Web of Science ®Google Scholar
• Baum RA, Bailey A, Chan R, et al. Suspected synthetic cannabinomimetic intoxication: case series and review. J Pharm Pract. 2018;31:238–243.
   Web of Science ®Google Scholar
• Bertol E, Pascali J, Palumbo D, et al. 3-MeO-PCP intoxication in two young men: first in vivo detection in Italy. Forensic Sci Int. 2017;274:7–12.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Kithinji J, Spehl M, et al. Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Test Anal. 2016;8:1030–1038.
   PubMed Web of Science ®Google Scholar
• Kirgiz A, Kaldirim H. Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication. Int Ophthalmol. 2019;39:237–241.
   Web of Science ®Google Scholar
• Waugh J, Najafi J, Hawkins L, et al. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. Clin Toxicol (Phila). 2016;54:512–518.
   PubMed Web of Science ®Google Scholar
• Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol (Phila). 2016;54:638–643.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Muller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol. 2018;56:404–411.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Gieron J, Gil D, et al. The effects of synthetic cannabinoid UR-144 on the human body-A review of 39 cases. Forensic Sci Int. 2017;273:e18–e21.
   PubMed Web of Science ®Google Scholar
• Besli GE, Ikiz MA, Yildirim S, et al. Synthetic cannabinoid abuse in adolescents: a case series. J Emerg Med. 2015;49:644–650.
   PubMed Web of Science ®Google Scholar
• Gee P, Schep LJ, Jensen BP, et al. Case series: toxicity from 25B-NBOMe - A cluster of N-bomb cases. Clin Toxicol. 2016;54:141–146.
   PubMed Web of Science ®Google Scholar
• Coppola M, Mondola R. JWH-122 consumption adverse effects: a case of hallucinogen persisting perception disorder five-year follow-up. J Psychoactive Drugs. 2017;49:262–265.
   PubMed Web of Science ®Google Scholar
• Forrester MB. NBOMe Designer drug exposures reported to Texas poison centers. J Addict Dis. 2014;33:196–201.
   PubMed Web of Science ®Google Scholar
• Madsen GR, Petersen TS, Dalhoff KP. NBOMe hallucinogenic drug exposures reported to the Danish Poison Information Centre. Dan Med J. 2017 Jun;64(6):A5386.
   Google Scholar
• Hermanns-Clausen M, Angerer V, Kithinji J, et al. Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. Clin Toxicol (Phila). 2017;55:922–924.
   Web of Science ®Google Scholar
• Abbara C, Ferec S, Leroux G, et al. 2,5-dimethoxy-4-chloroamphetamine, a LSD-like designer drug: clinical and analytical documentation of non-fatal exposure in five patients. Toxicologie Analytique et Clinique. 2017;29:82–89.
   Web of Science ®Google Scholar
• Srisuma S, Bronstein AC, Hoyte CO. NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol. 2015;53:624–628.
   PubMed Web of Science ®Google Scholar
• Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011;49:499–505.
   PubMed Web of Science ®Google Scholar
• Smolinske SC, Rastogi R, Schenkel S. Foxy methoxy: a new drug of abuse. J Med Toxicol. 2005;1:22–25.
   Google Scholar
• Kihara R, Day E. Transient psychotic episodes following recreational use of NRG-3. Prog Neurol Psychiatry. 2014;18:14–18.
   Google Scholar
• Mangold AR, Bravo TP, Traub SJ, et al. Flashback phenomenon and residual neurological deficits after the use of “bath salt” 3, 4-methylenedioxypyrovalerone. World J Emerg Med. 2014;5:63–66.
   PubMedGoogle Scholar
• Helander A, Backberg M, Signell P, et al. Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project. Clin Toxicol (Phila). 2017;55:589–599.
   PubMed Web of Science ®Google Scholar
• Peragallo J, Biousse V, Newman NJ. Ocular manifestations of drug and alcohol abuse. Curr Opin Ophthalmol. 2013; 24:566–573.
   Web of Science ®Google Scholar
• French DD, Margo CE, Harman LE. Substance use disorder and the risk of open-angle glaucoma. J Glaucoma. 2011;20:452–457.
   Web of Science ®Google Scholar
• Vroegop MP, Franssen EJ, van der Voort PHJ et al. The emergency care of cocaine intoxications. Neth J Med. 2009;67:122–126.
   PubMed Web of Science ®Google Scholar